Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (NCT06451770)
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
🩺 Plain-English Summary (8th-Grade Level)
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Who can join: Review the eligibility criteria below.
Location: Clinical Study Center — Clearwater, Florida
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Clinical Study Center — Clearwater, Florida
- Clinical Study Center — Miami Lakes, Florida
- Clinical Study Center — Port Orange, Florida
- Clinical Study Center — New York, New York
- Clinical Study Center — Adelaide,
- Clinical Study Center — Melbourne,
- Clinical Study Center — Chicoutimi,
- Clinical Study Center — Montreal,
- Clinical Study Center — Toronto,
- Clinical Study Center — Amsterdam,
- Clinical Study Center — Cape Town,
- Clinical Study Center — Johannesburg,
- Clinical Study Center — Liverpool,
- Clinical Study Center — London,
- Clinical Study Center 2 — Manchester,
- Clinical Study Center — Manchester,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hypercholesterolemia
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension — Daphne, Alabama
- Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy — Baltimore, Maryland
- Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile — Addison, Illinois
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia — Anniston, Alabama
- Causes and Natural History of Dyslipidemias — Bethesda, Maryland
Explore by condition: All Hypercholesterolemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.